Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 15, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
Ida Sonni, Ely R Felker, Andrew T Lenis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 12, 2026
Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA
John Nikitas, Adrien Holzgreve, Jesus Juarez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, et al.
Npj Imaging
|
January 6, 2026
Noninvasive in vivo deoxycytidine kinase (dCK)-PET identifies tumor-draining lymph nodes upon immune checkpoint inhibitor therapy
Cécile Philippe, Jonathan Cotton, Gregory D Bowden, et al.
Science Translational Medicine
|
January 20, 2017
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Khun Visith Keu, Timothy H Witney, Shahriar Yaghoubi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
<sup>68</sup>Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Riccardo Mei, Lukas Kessler, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U Kishan, Luca F Valle, Holly Wilhalme, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 15, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
Ida Sonni, Ely R Felker, Andrew T Lenis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 12, 2026
Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA
John Nikitas, Adrien Holzgreve, Jesus Juarez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, et al.
Npj Imaging
|
January 6, 2026
Noninvasive in vivo deoxycytidine kinase (dCK)-PET identifies tumor-draining lymph nodes upon immune checkpoint inhibitor therapy
Cécile Philippe, Jonathan Cotton, Gregory D Bowden, et al.
Science Translational Medicine
|
January 20, 2017
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Khun Visith Keu, Timothy H Witney, Shahriar Yaghoubi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
<sup>68</sup>Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Riccardo Mei, Lukas Kessler, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U Kishan, Luca F Valle, Holly Wilhalme, et al.
Page
of 5